Oppenheimer & Co. Inc.’s Post

Immuron (NASDAQ:IMRN, ASX:IMC) has received a bull case valuation of A$0.35 and a base case valuation of A$0.25 from Pitt Street Research in a report. The analysts highlight that the key catalysts for realising this potential shareholder value are the advancement of the company’s clinical-stage assets through the clinic with the end goal of bringing these assets to market. Immuron’s shares are currently trading on the ASX at A$0.072 with a market cap of A$17.1 million. More at http://ow.ly/VZUb104ZLsQ #NASDAQ #ASX #IMRN #IMC #Proactive #ProactiveInvestors #Immuron #Healthcare #Pharma

Over 60% of enrollees in standalone prescription drug plans could see an increase of at least 30% in their premium for 2024, according to #AvalereExperts' analysis of the 2024 #PartD landscape file. Stay tuned for more key takeaways and connect with us for additional details: https://lnkd.in/eWHHXKNx #Medicare #HealthPlans

IMMURON LIMITED (NASDAQ:IMRN, ASX:IMC) has secured an At-the-Market (ATM) funding facility with HC Wainwright and Co LLC, which will provide the Australian biotech with around US$2 million in funding. The company has filed a Form F-3 registration statement and ATM prospectus with the United States Securities and Exchange Commission (SEC). The Form F-3 allows Immuron, as a 'foreign private issuer', to raise up to US$15 million in the United States over a three-year period. This supersedes the company's recently expired US$100 million Form F-3 announced on April 9, 2019. The Form F-3 maintains Immuron’s flexibility with direct access to US capital markets. ATM funding facilities are widely used in the US and are becoming commonplace in Australia. More at #Proactive #ProactiveInvestors #ASX #IMC #Biotech #SEC #AntibioticResistance http://ow.ly/3fZO105z6ho

Here at Affygility Solutions, we often hear CDMO clients express their desire to handle Category 5 compounds. However, what they may not realize is the significant capital investment required to achieve this goal. Handling Category 5 compounds involves a variety of complex and costly measures, including facility modifications, investments in containment equipment, and personnel training. Moreover, the regulatory requirements for working with these compounds can be quite extensive. Therefore, it's important for organizations to carefully consider their goals and resources before pursuing the handling of Category 5 compounds. At Affygility Solutions, we work closely with clients to help them navigate these challenges and make informed decisions. cc/ Casey Cosner, PhD, CIH, CHMM #AffygilitySolutions #Category5Compounds #RegulatoryCompliance

This is big - #AvalereExperts are analyzing the 2024 #Part D landscape file and we are seeing many areas where the Part D market may look substantially different in 2024 compared to 2023. We are especially keeping an eye on PDPs and #LIS benchmark plans.

Sterne Kessler has been recognized for achievements in life sciences patent litigation, prosecution, and strategy in the 2023 LMG Life Sciences firm rankings. Additionally, Directors Eldora Ellison, Ph.D.; Carla Ji-Eun Kim; Gaby Longsworth, Ph.D.; J.C. Rozendaal; Eric Steffe; Deborah Sterling, Ph.D.; and Dennies Varughese, Pharm.D., were named as “Life Sciences Stars.” Read our press release to learn more about LMG Life Sciences’ annual rankings program. #LMGLifeSciences2023 #LifeSciences #Pharma #Biotech #PatentLitigation

At Scendea, we know that activity doesn’t stop over the summer. During the month of August, we are delighted to offer a 30-minute virtual meeting with our team, to allow us to learn more about your current activities and explore your product development and regulatory needs. - Book a meeting now with Stuart Hunter - https://lnkd.in/e_7fBnh9 - #ProductDevelopment #IntroductoryCall #RegulatoryAffairs #DrugDevelopment

Tissue Regenix reports its unaudited interim results for the six months ended 30 June 2023. Highlights ⬆ Group revenues increased by 19% to $14.1m  💰 Gross profit for the period increased to 49% ✅ Adjusted EBITDA profit of $0.4m. The Group has now been profitable on an adjusted EBITDA basis for the last twelve months 💵 Cash position of $4.1m  📈 Sixth consecutive reporting period of growth and the fifth consecutive period of double-digit half-on-half growth 🌏 Addition of a UK distributor for OrthoPure XT and distribution agreements for China and Australia 📊 15% year-on-year increase in processing throughput during H1 2023, as a result of the Phase 1 capacity expansion 🧬 37% increase in finished product availability for the OrthoPure XT product in H1 2023 Daniel Lee, Chief Executive Officer of Tissue Regenix Group plc, said: "We are extremely pleased with the growth seen by the Company in H1 2023, which is our sixth consecutive reporting period of growth. We retain a strong cash position to support our current business growth plans and we continue to reap the benefits and efficiencies of the Phase 1 capacity expansion at our San Antonio facility.   "We continue to see increased sales for our dCELL and BioRinse product families which have contributed to our first 12 months of profitability on an adjusted EBITDA basis. It has been a strong period for Tissue Regenix, having outperformed the market in respect of growth in our key businesses and in H2 2023 we look forward to continuing our successes through additional partnerships and product lines. We continue to build on our momentum and expect 2023 to be another year of above market growth."   Read the full announcement here: https://lnkd.in/dgYUNeC

There are lies, there are damn lies, and then there are the blatant, intentional falsehoods that IMAK tells in order to get people to believe something that is not true. For example, they continue to say that there is no generic form of #Lyrica available, yet generic Lyrica has been on the market since July 2019. How can you believe anything IMAK says when the lies they tell are so easily proven to be false? #patent #patents #pharmaceuticals #drugs #generics https://lnkd.in/gGqV-RhC

BcFG is coming closer to reality everyday. 1. Land purchase is nearing completion -> will start building. 2. CDMO of interest identified for particular drug formulations and administration routes. 3. Potential venture capitol investors communicating with. 4. Business is set to become a reality once Land purchase is closed. 5. Trademark and copyright will be next. 6. Licensing of the patent to BcFG from myself. 7. Finalization of venture capitol and CDMO partners. 8. Clinical trials 9. FDA approval 10. Market - We will also be selling antiseptics without FDA approval meant for surface disinfection.(but if you chose to use them on yourself could work as a topical, but would be strongly discouraged) #BcFG #antibiotics #antiseptics #business #venturecapitol #venture #money #funding #invest #investment #changetheworld #licensing #clinicaltrials #drugs #steps #stepbystep #makingprogress #alwaysprogressing